NVision Imaging Technologies
NVision Imaging Technologies develops quantum-enhanced MRI (POLARIS) and molecular quantum computing (PIQC) platforms based on engineered organic molecules. It serves leading cancer research institutions with metabolic imaging devices and targets drug discovery applications for previously undruggable targets.
- Company typePrivate
- Founded2016
- HeadquartersUlm, Germany
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What NVision Imaging Technologies does
NVision Imaging Technologies GmbH (operating as NVision Quantum Technologies) is a German quantum-technology company founded in 2016 and headquartered in Ulm. It has built two product platforms from a common underlying capability in engineered molecular quantum systems. POLARIS is a quantum-enhanced MRI device that uses parahydrogen-induced polarization to boost the magnetic signal of engineered sugar molecules by over 10,000x, enabling real-time metabolic imaging of tumors without radioactive radiation. PIQC is the company's molecular quantum computing platform, in which engineered organic carbene molecules act as long-lived qubits with intrinsic photonic interfaces, with the company having demonstrated first optical control of quantum information in a single molecule and spin lifetimes exceeding 2 milliseconds at 4 kelvins.
The company's commercial motion is enterprise and research-focused: POLARIS is deployed at leading cancer research institutions (initial deployment at Memorial Sloan Kettering Cancer Center, with plans to reach 20 centers across the U.S., Europe, and Asia by year-end 2026), while PIQC is positioned for downstream applications in drug discovery for previously undruggable targets. Revenue today is a mix of grant income from European public funding sources (over EUR 35 million since 2022, including EUR 15 million from the European Investment Bank), emerging POLARIS hardware sales or leasing to research centers, and future potential licensing or royalty streams from quantum-computing-enabled drug discovery. A $55 million Series B in May 2026 led by Abbott, alongside Playground Global, b2venture, Entree Capital, Lauder, and Pathena, valued the company at over $250 million.
The company was co-founded by CEO Sella Brosh (former McKinsey senior engagement manager) and CTO Ilai Schwartz (PhD, Ulm University), together with scientific co-founders Prof. Martin Plenio (75,000+ citations, Alexander von Humboldt Professorship), Prof. Fedor Jelezko (Zeiss Research Award), and Prof. Alex Retzker, giving it deep ties to Ulm University, Hebrew University, and Aarhus University. The company is pursuing FDA approval for human clinical studies in 2027, indicating an intent to transition POLARIS from a research tool into a regulated clinical device.
NVision Imaging Technologies firmographics
Firmographics- Name
- NVision Imaging Technologies
- Legal name
- NVision Imaging Technologies GmbH
- Website
- https://nvision-imaging.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- NVision Imaging Technologies develops quantum-enhanced MRI (POLARIS) and molecular quantum computing (PIQC) platforms based on engineered organic molecules. It serves leading cancer research institutions with metabolic imaging devices and targets drug discovery applications for previously undruggable targets.
- Ownership category
- akta.pro rank
NVision Imaging Technologies industry classification
Industry- Product category
- Quantum Medical Imaging Equipment
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Scientific Research and Development Services (5417)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Magnetic Resonance Imaging (MRI) Systems (HLAHABAC)
- akta.pro secondary industries
- Quantum Photonics & Quantum Imaging (Single-Photon, Lidar, Ghost Imaging) (HDAGAHAF), Quantum Magnetometry (SQUID/OPM/NV and related) (HDAGAHAD), Optoelectronics & Photonics (LED/Laser/Optical ICs) (HDAHAAAH)
Keywords
Where NVision Imaging Technologies is headquartered
LocationHeadquarters
- HQ city
- Ulm
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
NVision Imaging Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- POLARIS Device Sales/Leasing: NVision generates revenue through the deployment and sale of its POLARIS quantum-enhanced MRI device to cancer research institutions. The Polaris device is deployed at leading research centers, suggesting a hardware sales or leasing model for research institutions.
- Quantum Computing Platform (PIQC): The company leverages its quantum computing breakthrough to design new drugs for previously undruggable targets, potentially opening future revenue streams through pharmaceutical partnerships and drug discovery collaborations.
- Research Grants and Public Funding: NVision receives significant public funding through European research consortiums, including grants from the European Investment Bank, Innovation Fund Denmark, and ERC Synergy Grants, supporting R&D across quantum-enhanced MRI and quantum computing.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
NVision Imaging Technologies product offering
Product offeringCore offering
NVision develops and manufactures the POLARIS quantum-enhanced MRI system, which uses parahydrogen-induced polarization to amplify the magnetic signal of engineered sugar molecules by over 10,000x, enabling real-time metabolic imaging of tumors for cancer diagnosis and treatment response monitoring. The company also develops PIQC, a molecular quantum computing platform based on engineered organic carbene molecules with photonic interfaces, positioned as the foundation for the world's first molecular quantum computer. POLARIS devices are sold or leased to leading cancer research institutions, with Memorial Sloan Kettering Cancer Center as the first deployment site.
Product overview
NVision offers two main quantum technology platforms: POLARIS is a quantum-enhanced MRI system that boosts MRI signal sensitivity by over 10,000x through parahydrogen-induced polarization of engineered sugar molecules, enabling real-time metabolic imaging for cancer diagnosis and treatment monitoring. PIQC is a molecular quantum computing platform based on engineered organic molecules with long-lived qubits integrated natively on photonic chips, designed for scalability and forming the foundation for quantum computing applications. Both technologies leverage molecular quantum systems engineered at the molecular level, with POLARIS focused on quantum sensing for medical imaging and PIQC targeting quantum computing.
Differentiator
Problem solved
Functional benefit
Products and services
- POLARIS Quantum-Enhanced MRI Quantum-enhanced MRI device that boosts the magnetic signal of engineered sugar molecules by over 10,000x using parahydrogen-induced polarization, making metabolic activity in cancer cells visible to MRI in real time without radioactive radiation. Targets cancer research institutions and oncology centers for tumor diagnosis, treatment response monitoring, and earlier cancer detection.
- PIQC (Photonic Integrated Quantum Computing) Platform The first quantum computing platform based on molecular quantum nodes native to photonic chips, where engineered organic molecules combine long-lived qubits with intrinsic photonic interfaces in a scalable architecture. Designed as the foundation for the world's first molecular quantum computer, with future applications in drug discovery for previously undruggable targets.
Quantifiable outcome
- Cancer treatment feedback cycle reduced from months to days
- +4 more outcomes
Companies that use NVision Imaging Technologies
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
NVision Imaging Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
NVision Imaging Technologies partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and notable.
- Aarhus UniversitycoreNVision Imaging Technologies GmbH and Aarhus University were jointly awarded a €5.4 million (40m DKK) grant under Denmark's Grand Solutions in Quantum Technologies program for the MIRAQLE project. The project aims to advance clinical translation of quantum-enhanced MRI for early liver cancer diagnostics, leveraging NVision's POLARIS technology.
- Memorial Sloan Kettering Cancer CentercoreMemorial Sloan Kettering Cancer Center is using NVision's Polaris quantum-based hyperpolarized metabolic MRI device in oncological preclinical studies, marking the first deployment of the technology at a leading cancer research institution. This represents a key clinical validation partnership.
- SPINNING Project ConsortiumnotableNVision participates in the SPINNING project, a joint initiative developing a diamond spin-photon-based quantum computer demonstrator involving six universities, two non-profit research institutions, five industrial companies, and fourteen associated partners, coordinated by Fraunhofer IAF and funded by the German Federal Ministry of Education and Research.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
NVision Imaging Technologies competitors and assessment
Company assessmentBroad incumbents
- Siemens Healthineers: One of the world's largest MRI system manufacturers, with a deep installed base in hospitals and research centers. Highly comparable to NVision as the dominant incumbent POLARIS would need to integrate alongside or differentiate from; also a likely strategic-partner or acquirer given NVision's Ulm/German footprint.
- GE HealthCare: Global MRI incumbent with broad hospital distribution and a strategic focus on precision diagnostics. Directly comparable as a peer whose installed MRI base represents both the integration target for POLARIS and the primary competitive incumbent for any future quantum-enhanced MRI workflow.
- Quantinuum: One of the largest standalone quantum computing companies, combining trapped-ion hardware with a full software stack. Comparable to NVision as a peer targeting pharmaceutical and materials-science customers that overlap with NVision's stated drug-discovery use cases for PIQC.
Direct peers
- Bruker: Manufactures preclinical MRI and NMR systems including hyperpolarization instrumentation for research institutions. The closest direct comparable to NVision on the hyperpolarized-metabolic-imaging side, serving the same cancer-research buyer with adjacent technology.
- PsiQuantum: Photonic quantum computing company pursuing fault-tolerant quantum systems and explicitly co-presented with NVision at quantum-industry events. The most directly comparable peer for NVision's PIQC platform given the shared photonic-chip architecture and similar technical ambition.
- Xanadu Quantum Technologies: Photonic quantum computing company developing scalable, room-temperature quantum systems. Comparable to NVision on PIQC's photonic-chip architecture and on the strategy of building full-stack quantum hardware for both computing and sensing use cases.
- Magnetic Insight: Specializes in magnetic particle imaging and hyperpolarized contrast agents for preclinical research. Highly comparable to NVision's POLARIS business on the hyperpolarization-and-preclinical-oncology-imaging axis, serving the same cancer-research customer base.
- IonQ: Trapped-ion quantum computing company pursuing both general-purpose quantum advantage and pharma-relevant applications. Comparable to NVision on the quantum-computing side of PIQC, particularly for the drug-discovery-for-undruggable-targets value proposition.
Emerging players
- Phasecraft: Early-stage quantum algorithms company co-presented with NVision at industry events and focused on near-term quantum advantage for materials and chemistry. Comparable to NVision as a fellow emerging quantum-computing peer targeting pharmaceutical and chemistry applications.
- Qnami: Quantum sensing company using NV-center diamond technology for nanoscale imaging, with academic roots overlapping NVision's Ulm ecosystem. Comparable to NVision on the quantum-sensing and NV-center IP foundation underlying both POLARIS and PIQC.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
NVision Imaging Technologies social profiles
Digital presenceNVision Imaging Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
NVision Imaging Technologies leadership team
Management profileNumber of profiles
Profiles5 records
NVision Imaging Technologies funding detail
Funding detailFunding overview
Funding rounds20 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NVision Imaging Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NVision Imaging Technologies
What does NVision Imaging Technologies do?
NVision develops and manufactures the POLARIS quantum-enhanced MRI system, which uses parahydrogen-induced polarization to amplify the magnetic signal of engineered sugar molecules by over 10,000x, enabling real-time metabolic imaging of tumors for cancer diagnosis and treatment response monitoring. The company also develops PIQC, a molecular quantum computing platform based on engineered organic carbene molecules with photonic interfaces, positioned as the foundation for the world's first molecular quantum computer. POLARIS devices are sold or leased to leading cancer research institutions, with Memorial Sloan Kettering Cancer Center as the first deployment site.
Is NVision Imaging Technologies a public or private company?
NVision Imaging Technologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was NVision Imaging Technologies founded?
NVision Imaging Technologies was founded in 2016. It employs 101 to 250 people.
Where is NVision Imaging Technologies based?
NVision Imaging Technologies is headquartered in Ulm, Germany, in the Europe region.
How does NVision Imaging Technologies make money?
Three revenue lines are on record. POLARIS Device Sales/Leasing is the primary driver. The others are quantum Computing Platform (PIQC) and research Grants and Public Funding.
Who are NVision Imaging Technologies's main competitors?
Broad incumbents on record are Siemens Healthineers, GE HealthCare and Quantinuum. Direct peers are Bruker, PsiQuantum, Xanadu Quantum Technologies, Magnetic Insight and IonQ. Emerging players are Phasecraft and Qnami.
Does NVision Imaging Technologies have an API?
No public API is recorded for NVision Imaging Technologies.
What industry is NVision Imaging Technologies in?
NVision Imaging Technologies's product category is Quantum Medical Imaging Equipment. Its primary akta.pro industry code is HLAHABAC, Magnetic Resonance Imaging (MRI) Systems, with a secondary code of HDAGAHAF, Quantum Photonics & Quantum Imaging (Single-Photon, Lidar, Ghost Imaging). Its NAICS code is 334510 and its SIC code is 3845.